Drugs / Ex vivo Expanded Human Autologous Regulatory T Cells
Ex vivo Expanded Human Autologous Regulatory T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06708780 | Apr 2023 → Dec 2026 expected | type 1 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ex vivo Expanded Human Autologous Regulatory T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06708780 ↗ |
| Modality | Cell therapy | “autologous Treg transplantation” NCT06708780 ↗ |